News headlines about CryoLife (NYSE:CRY) have been trending somewhat positive this week, Alpha One reports. Alpha One, a subsidiary of Accern, identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CryoLife earned a daily sentiment score of 0.13 on Alpha One’s scale. Alpha One also gave media headlines about the medical equipment provider an impact score of 43 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
CryoLife (NYSE CRY) traded up 0.27% during trading on Friday, reaching $18.50. 201,535 shares of the company were exchanged. The firm has a 50-day moving average of $18.56 and a 200-day moving average of $17.88. The firm has a market cap of $615.31 million, a price-to-earnings ratio of 60.06 and a beta of 1.05. CryoLife has a 52-week low of $11.35 and a 52-week high of $20.15.
CryoLife (NYSE:CRY) last released its quarterly earnings data on Wednesday, April 26th. The medical equipment provider reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.05. The company had revenue of $45.10 million during the quarter, compared to analyst estimates of $44.64 million. CryoLife had a net margin of 5.73% and a return on equity of 7.77%. CryoLife’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. On average, equities analysts forecast that CryoLife will post $0.43 EPS for the current year.
Several research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Thursday, June 8th. Northland Securities restated a “buy” rating and issued a $23.50 price target on shares of CryoLife in a research report on Friday, April 28th. Finally, Ladenburg Thalmann Financial Services upgraded shares of CryoLife from a “neutral” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Friday, February 17th. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $20.80.
TRADEMARK VIOLATION NOTICE: “CryoLife (CRY) Getting Somewhat Favorable Press Coverage, Study Finds” was reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.themarketsdaily.com/2017/06/16/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-cryolife-cry-share-price-updated.html.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.